SWOG clinical trial number
S0517
A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma -
77% Accrual
Accrual
77%
Closed
Phase
77% Accrual
Accrual
77%
Published
Abbreviated Title
HODGKIN'S: SAHA for Recurrent or Primary Refractory Hodgkin's Lymphoma
Activated
09/15/2005
Closed
08/01/2007
Participants
Research committees
Lymphoma
Treatment
Suberoylanilide Hydroxamic Acid (SAHA; Vorinostat)
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
21% Accrual
Accrual
21%
Open
Phase
S2207
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase